Second Shot at Alzheimer's Proves Unsuccessful for vTv Therapeutics' Azeliragon

vTv Therapeutics, based in High Point, North Carolina, announced that its Phase II Elevage study of azeliragon in mild Alzheimer’s disease and type 2 diabetes failed to hit its primary objective. The goal was to show improvement in cognition on the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) compared to placebo.